The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation

Clopidogrel, ticagrelor and prasugrel are routinely used for platelet inhibition in addition
to aspirin in patients after acute coronary syndromes. The platelet inhibition and patient
outcomes (PLATO) trial showed that in patients with acute coronary syndromes, ticagrelor
significantly reduced the primary endpoint (cardiovascular death, myocardial infarction or
stroke), all-cause mortality and cardiovascular mortality compared to clopidogrel. On the
other hand, when compared with clopidogrel in patients with acute coronary syndromes with
scheduled percutaneous coronary intervention, prasugrel therapy did not affect overall
mortality despite the fact that it was associated with significantly reduced rates of
ischemic events, including stent thrombosis, but with an increased risk of major bleeding,
including fatal bleeding. This may suggest that ticagrelor possesses additional
(pleiotropic) effects besides platelet inhibition.

The investigators have recently shown that pioglitazone increases 15-epi-lipoxin A4 blood
levels in patients. The investigators have recently found that in the rat, ticagrelor
increases tissue levels of 15-epi-lipoxin A4 in the heart, aorta and kidney.

It is plausible that some of the favorable effects of ticagrelor seen in the clinical
studies are mediated via the anti-inflammatory effects of 15-epi-lipoxin A4.

15-epi-lipoxin A4 is a potent anti-inflammatory and inflammation-resolving mediator derived
from arachidonic acid. Several studies have suggested that ticagrelor has anti-inflammatory
properties in various animal models. In the present study the investigators will assess if
ticagrelor increases blood 15-epi-lipoxin A4 levels at doses used in patients.

Inclusion Criteria:

Provision of informed consent prior to any study specific procedures

Women of childbearing potential must be using an acceptable method of contraception to
avoid pregnancy throughout the study

Patients with stable coronary artery disease (3-12 months after Acute Coronary Syndrome)
who receive clopidogrel for at least 3 months.

Exclusion Criteria:

Recent stroke or acute coronary syndromes (<3 months before randomization).

Concurrent use of aspirin >100 mg/day where the dose reduction to 81 mg/day is
contraindicated.

Current use of theophylline.

Concurrent use of Non Steroidal Anti-Inflammatory Drugs.

Patients receiving the following medications: ketoconazole, itraconazole, voriconazole,
clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir,
telithromycin, rifampin, dexamethasone, phenytoin, carbamazepine, or phenobarbital.
Patients receiving simvastatin or lovastatin at doses greater than 40 mg daily.

Patients with type 2 diabetes with a fasting plasma glucose greater than 200 mg/dl.

Active inflammatory disease or chronic infection.

Contraindication for aspirin, clopidogrel or ticagrelor.

Women who are pregnant or breastfeeding.